
ORIGINAL



KAW

Meraki, Inc. ("Meraki") hereby alleges for its complaint against defendant ClearPath Networks, Inc. ("ClearPath"), on personal knowledge as to its own activities and on information and belief as to the activities of others, as follows:

NATURE OF THIS ACTION

1. This is an action for declaratory judgment of noninfringement and invalidity of three United States patents pursuant to the Declaratory Judgment Act, 28 U.S.C. §§ 2201-2202, and the United States Patent Law, 35 U.S.C. § 100 et seq., and for such other relief as the Court deems just and proper.

THE PARTIES

- 2. Plaintiff Meraki is a corporation organized and existing under the laws of Delaware, with its principal place of business at 660 Alabama Street, San Francisco, California 94110. Meraki is a leader in cloud networking offering easy-to-deploy on-premise networking solutions that can be centrally managed from the cloud.
- 3. Meraki's products have collected accolades from the industry press and have been described as "game changers." Meraki was termed a "visionary" in Gartner's 2012 Magic Quadrant for Wired and Wireless LAN Infrastructure which "excels in the delivery of network service applications beyond typical vendors" and has a "loyal customer base." Meraki also was named one of CRN's 25 Coolest Emerging Vendors for 2012, and its Enterprise Cloud Platform was named an Infoworld 2012 Technology of the Year Award Winner.
- 4. On November 18, 2012, Cisco Systems, Inc. ("Cisco") announced its intention to acquire Meraki for approximately \$1.2 billion. On December 20, 2012, Cisco's acquisition of Meraki was completed. Meraki now is a wholly-owned subsidiary of Cisco.
- 5. On information and belief, Defendant ClearPath Networks, Inc. ("ClearPath") is a Delaware corporation with its principal place of business at 300 North Continental Boulevard, Suite 400, El Segundo, California 90245.

INTRADISTRICT ASSIGNMENT

6. Pursuant to Civil Local Rule 3-2(c), this is an Intellectual Property Action to be assigned on a district-wide basis.

BACKGROUND

- 7. United States Patent No. 7,783,800 ("the '800 patent") is entitled "Systems and Methods for Managing a Network." The '800 patent states that it issued on August 24, 2010. A true and correct copy of the '800 patent is attached as Exhibit A.
- 8. United States Patent No. 8,078,777 ("the '777 patent") is entitled "Systems and Methods for Managing a Network." The '777 patent states that it issued on December 13, 2011. A true and correct copy of the '777 patent is attached as Exhibit B.
- 9. United States Patent No. 8,341,317 issued from application Serial No. 13/272,311 and states that it issued on December 25, 2012. Collectively, United States Patent No. 8,341,317 and application Serial No. 13/272,311 are referred to as "the '317 patent." The '317 patent is entitled "Systems and Methods for Managing a Network." A true and correct copy of the '317 patent is attached as Exhibit C. The '800 patent, the '777 patent, and the '317 patent are collectively referred to as the "ClearPath patents." The ClearPath patents are related patents all stemming from a common parent application.
- 10. On November 18, 2012, Cisco announced its intention to acquire Meraki in a deal valued at approximately \$1.2 billion.
- 11. On November 28, 2012, counsel for ClearPath, James R. Kyper, wrote to Meraki CEO, Sanjit Biswas, claiming ClearPath "launched the world's first cloud managed network services platform" and asserting ClearPath's '800 and '777 patents, and its then-pending application Serial No. 13/272,311 which issued as the '317 patent, "include claims that are applicable to certain offerings of Meraki." The letter included a claim chart that purported to "illustrate[] how the elements of Claim 1 of the '800 patent can be readily mapped to certain aspects of Meraki's products and services." The letter continued that "infringement of ClearPath's patent rights by Meraki is apparent," and stated that ClearPath is "open to discussing an amicable resolution to this situation prior to pursuing legal proceedings or filing a complaint in federal court." A true and correct copy of ClearPath's November 28 letter is attached as Exhibit D.
- 12. On November 28, 2012, ClearPath's CEO Cliff Young also wrote to Cisco asserting, among other things, that ClearPath's "patented technology is being pervasively

 infringed upon by the core Meraki platform" and that "[t]he methods used and capabilities offered are identical in many respects to how we have done it since 2003."

- 13. On December 7, 2012, Mr. Young sent an email to Meraki's investors. That email stated that ClearPath "became aware of Meraki's core cloud managed network services capability" "[f]ollowing the recent announcement of the Meraki acquisition" and said ClearPath was "quite stunned to learn that [its] patented technology is being pervasively infringed upon by the Meraki core platform." Mr. Young also quoted a Meraki investor's blog posting which referred to "cloud-based software to control the hardware" and asserted that the methods described in that posting "are identical in many respects to exactly how we have done it since 2003."
- 14. On December 20, 2012, after Cisco completed its acquisition of Meraki, representatives of ClearPath, Meraki, and Cisco met in San Francisco, California to discuss a potential resolution. At the meeting, ClearPath reasserted its belief that Meraki infringes the ClearPath patents.
- 15. Following that meeting, on January 2, 2013, ClearPath provided a licensing proposal to Meraki entitled "FINAL SETTLEMENT PROPOSAL." ClearPath's "FINAL SETTLEMENT PROPOSAL" to Meraki reconfirmed that ClearPath accuses Meraki of infringing the '800, '777, and '317 patents. It demands licensing fees that vastly exceed the value, if any, of the asserted patents, and it threatens imminent litigation against Meraki unless Meraki acquiesces to ClearPath's proposal.

JURISDICTION AND VENUE

- 16. This Court has exclusive subject matter jurisdiction pursuant to 28 U.S.C. §§ 1331, 1338(a), 2201, and 2202, and the Patent Laws of the United States, 35 U.S.C. § 1 *et seq*.
 - 17. Venue is proper in this judicial district under 28 U.S.C. § 1391.
- 18. Meraki and its products have not infringed and do not infringe, either directly or indirectly, any valid and enforceable claim on any of the ClearPath patents, and thus Meraki does not require a license to the ClearPath patents. In view of ClearPath's repeated and express allegations of infringement against Meraki and threats to file suit against Meraki, a substantial / / /

3

4

5 6

8

7

10

9

13

11

17

18

19

20 21

22

23

25

27

111

111

28

controversy exists between the parties which is of sufficient immediacy and reality to warrant declaratory relief.

FIRST CAUSE OF ACTION (Declaratory Judgment of Invalidity of U.S. Patent No. 7,783,800)

- 19. Meraki repeats and realleges each and every allegation set forth in paragraphs 1 through 18, inclusive, and incorporates them by reference herein.
- 20. ClearPath contends that Meraki is infringing the '800 patent, including without limitation because of Meraki's MX product (the product used in ClearPath's exemplary claim chart), and needs to license the '800 patent.
- 21. The '800 patent is invalid because it fails to satisfy the conditions and requirements for patentability as set forth, inter alia, in Sections 101, 102, 103, and/or 112 of Title 35 of the United States Code. On information and belief, the '800 patent is invalid, for example, because ClearPath offered for sale products and services that practice the claims of the '800 patent more than one year before the claimed priority date of the '800 patent. As discussed above, ClearPath's CEO quoted Meraki's investor's blog posting which referred to "cloud-based software to control the hardware" and asserted that the methods described "are identical in many respects to exactly how we have done it since 2003." ClearPath websites dating back to 2002 suggest the methods were used as early as 2002. Further, the '800 patent is invalid in view of, for example, U.S. Patent Nos. 6,587,874 and 6,012,088.
- 22. On at least the basis that the '800 patent is invalid, Meraki does not need a license to the '800 patent, and it has a right to continue providing products and services without a license to ClearPath's '800 patent.
- Accordingly, an actual, valid, and justiciable controversy has arisen and exists 23. between Meraki and ClearPath. A judicial determination and declaration are necessary and appropriate at this time in order that the parties may ascertain their respective rights and duties regarding the '800 patent.

COMPLAINT - DECLARATORY JUDGMENT

SECOND CAUSE OF ACTION (<u>Declaratory Judgment of Noninfringement of U.S. Patent No. 7,783,800</u>)

- 24. Meraki repeats and realleges each and every allegation set forth above in paragraphs 1 through 23, inclusive, and incorporates them by reference herein.
- 25. The accused Meraki products, including without limitation Meraki's MX product, have not infringed and do not infringe, directly or indirectly, any valid and enforceable claim of the '800 patent, either literally or under the doctrine of equivalents. Accordingly, Meraki does not need a license to the '800 patent, and it has a right to continue providing products and services without a license to or interference from ClearPath's '800 patent.
- 26. Accordingly, an actual, valid, and justiciable controversy has arisen and exists between Meraki and ClearPath. Meraki desires a prompt and definitive judicial determination and declaration that its products do not infringe any valid claim of the '800 patent. Such a determination and declaration are necessary and appropriate at this time in order that the parties may ascertain their respective rights and duties.

THIRD CAUSE OF ACTION (<u>Declaratory Judgment of Invalidity of U.S. Patent No. 8,078,777</u>)

- 27. Meraki repeats and realleges each and every allegation set forth in paragraphs 1 through 26, inclusive, and incorporates them by reference herein.
- 28. ClearPath contends that Meraki is infringing the '777 patent, including without limitation because of Meraki's MX product, and needs to license the '777 patent.
- 29. The '777 patent is invalid because it fails to satisfy the conditions and requirements for patentability as set forth, *inter alia*, in Sections 101, 102, 103, and/or 112 of Title 35 of the United States Code. On information and belief, the '777 patent is invalid, for example, because ClearPath offered for sale products and services that practice the claims of the '777 patent more than one year before the claimed priority date of the '777 patent. As discussed above, ClearPath's CEO quoted Meraki's investor's blog posting which referred to "cloud-based software to control the hardware" and asserted that the methods described "are identical in many respects to exactly how we have done it since 2003." ClearPath websites dating back to 2002 suggest the methods

were used as early as 2002. Further, the '777 patent is invalid in view of, for example, U.S. Patent Nos. 6,587,874 and 6,012,088.

- 30. On at least the basis that the '777 patent is invalid, Meraki does not need a license to the '777 patent, and it has a right to continue providing products and services without a license to ClearPath's '777 patent.
- 31. Accordingly, an actual, valid, and justiciable controversy has arisen and exists between Meraki and ClearPath. A judicial determination and declaration are necessary and appropriate at this time in order that the parties may ascertain their respective rights and duties regarding the '777 patent.

FOURTH CAUSE OF ACTION (Declaratory Judgment of Noninfringement of U.S. Patent No. 8,078,777)

- 32. Meraki repeats and realleges each and every allegation set forth above in paragraphs 1 through 31, inclusive, and incorporates them by reference herein.
- 33. The accused Meraki products, including without limitation Meraki's MX product, have not infringed and do not infringe, directly or indirectly, any valid and enforceable claim of the '777 patent, either literally or under the doctrine of equivalents. Accordingly, Meraki does not need a license to the '777 patent, and it has a right to continue providing products and services without a license to or interference from ClearPath's '777 patent.
- 34. Accordingly, an actual, valid, and justiciable controversy has arisen and exists between Meraki and ClearPath. Meraki desires a prompt and definitive judicial determination and declaration that its products do not infringe any valid claim of the '777 patent. Such a determination and declaration are necessary and appropriate at this time in order that the parties may ascertain their respective rights and duties.

FIFTH CAUSE OF ACTION (Declaratory Judgment of Invalidity of U.S. Patent No. 8,341,317)

35. Meraki repeats and realleges each and every allegation set forth in paragraphs 1 through 34, inclusive, and incorporates them by reference herein.

28 / / /

36. ClearPath contends that Meraki is infringing the '317 patent, including without limitation because of Meraki's MX product, and needs to license the '317 patent.

- 37. The '317 patent is invalid because it fails to satisfy the conditions and requirements for patentability as set forth, *inter alia*, in Sections 101, 102, 103, and/or 112 of Title 35 of the United States Code. On information and belief, the '317 patent is invalid, for example, because ClearPath offered for sale products and services that practice the claims of the '317 patent more than one year before the claimed priority date of the '317 patent. As discussed above, ClearPath's CEO quoted Meraki's investor's blog posting which referred to "cloud-based software to control the hardware" and asserted that the methods described "are identical in many respects to exactly how we have done it since 2003." ClearPath websites dating back to 2002 suggest the methods were used as early as 2002. Further, the '317 patent is invalid in view of, for example, U.S. Patent Nos. 6,587,874 and 6,012,088.
- 38. On at least the basis that the '317 patent is invalid, Meraki does not need a license to the '317 patent, and it has a right to continue providing products and services without a license to ClearPath's '317 patent.
- 39. Accordingly, an actual, valid, and justiciable controversy has arisen and exists between Meraki and ClearPath. A judicial determination and declaration are necessary and appropriate at this time in order that the parties may ascertain their respective rights and duties regarding the '317 patent.

SIXTH CAUSE OF ACTION (Declaratory Judgment of Noninfringement of U.S. Patent No. 8,341,317)

- 40. Meraki repeats and realleges each and every allegation set forth above in paragraphs 1 through 39, inclusive, and incorporates them by reference herein.
- 41. The accused Meraki products, including without limitation Meraki's MX product, have not infringed and do not infringe, directly or indirectly, any valid and enforceable claim of the '317 patent, either literally or under the doctrine of equivalents. Accordingly, Meraki does not need a license to the '317 patent, and it has a right to continue providing products and services without a license to or interference from ClearPath's '317 patent.

42. Accordingly, an actual, valid, and justiciable controversy has arisen and exists between Meraki and ClearPath. Meraki desires a prompt and definitive judicial determination and declaration that its products do not infringe any valid claim of the '317 patent. Such a determination and declaration are necessary and appropriate at this time in order that the parties may ascertain their respective rights and duties.

PRAYER FOR RELIEF

WHEREFORE, plaintiff Meraki requests entry of judgment in its favor and against defendant ClearPath as follows:

- (a) Declaring that the claims of the '800, '777, and '317 patents are invalid:
- (b) Declaring that Meraki has not infringed, induced others to infringe, or contributed to the infringement of any valid claim of the '800, '777, and '317 patents, either directly or indirectly, either literally or under the doctrine of equivalents;
- (c) Enjoining ClearPath, its officers, owners, partners, employees, agents, parents, subsidiaries, attorneys, and anyone acting in concert or participation with any of them, from making any claims that Meraki's products or services infringe the '800, '777, and '317 patents;
- (d) Enjoining ClearPath, its officers, owners, partners, employees, agents, parents, subsidiaries, attorneys, and anyone acting in concert or participation with any of them, from enforcing the '800, '777, and '317 patents;
- (e) Awarding Meraki its costs of suit, including reasonable attorneys' fees; and
- (f) Granting such other and further relief as the Court may deem just and proper.

Dated: January 10, 2013

WILSON SONSINI GOODRICH & ROSATI Professional Corporation

y: **BleKUU**

Stefani E. Shanberg

Attorneys for Plaintiff MERAKI, INC.

DEMAND FOR JURY TRIAL

Pursuant to Federal Rule of Civil Procedure 38 and Civil Local Rule 3-6(a), Meraki hereby demands a jury trial of all issues triable by a jury.

Dated: January 10, 2013

WILSON SONSINI GOODRICH & ROSATI Professional Corporation

By: Stefani E. Shanberg

Attorneys for Plaintiff MERAKI, INC.